Recent literature has shown that anecdotal evidence has supported the notion that CBD can exert a beneficial role, alone or in combination with THC, in different neurodegenerative disease, such as Parkinson’s disease and Huntington’s disease, two chronic disorders provoked by degenerative processes implicating specific nuclei of the basal ganglia, responsible for abnormal regulation of movements. Both disorders have been scantly investigated from the clinical point of view, whereas, at preclinical level, accumulated findings appear more exhaustive and convincing for a possible medical utilization of CBD to improve symptoms and/or delay disease progression. According to recent preclinical findings, plant‐derived cannaboids were able to prevent neuronal damage induced by 6‐hydroxydopamine unilateral injection. This effect appeared to not involve cannaboid receptor mediation, whereas, more likely, it might implicate the antioxidant activity, possibly combined with the capability to modulate glial responses, relevant to neural survival. In rodents with hemiparkinsonism, induced by the intranigral administration of 6‐hydroxydopamine, neuroprotective effects exerted by CBD antagonized dopaminergic transmission impairment by attenuating dopaminergic cell death, rather than by increasing the functional turnover of the surviving neurons . Early human reports showed a dose‐related improvement (ranging from 20 to 50%) in Parkinsonian patients treated with oral doses of CBD (100–600 mg/day over a 6‐week period) . On the contrary, in a more recent controlled trial, a mixture of THC/CBD (2.5 mg/1.25 mg per capsule) failed to exhibit any beneficial effect either on parkinsonism or on levodopa‐induced dyskinesias. Unfortunately, no subsequent trials were performed to elucidate such controversial findings. Certainly, in comparison to the relevance of rodent results, the limited clinical evidence suggests performance of human studies to verify for good the possible future clinical use of CBD in Parkinson’s Disease.